Boehringer Ingelheim plans to develop new immuno-oncology treatments for an undisclosed number of targets using PureTech Health’s lymphatic targeting technology for immune modulation, through a collaboration that PureTech said today could generate for it more than $226 million. The companies will initially focus on applying PureTech’s internally-developed lymphatic targeting platform to an unspecified Boehringer Ingelheim […]
The post Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies